SLU-PP-332 500mcg, 50 Tablets. Used to support energy metabolism, endurance, fat metabolism, and exercise performance. Lab tested, discreetly shipped across Canada
Format50 Tablets
Concentration500mcg
Pack Size Selected: 5 Pack
Pay with Interac e-Transfer or Crypto
HPLC verified. COA on file for this batch
Ships from within Canada; No Customs
Discreet plain packaging; always
24h dispatch; Tracked Delivery
SLU-PP-332 is a synthetic small molecule agonist of estrogen related receptors alpha and gamma (ERRα and ERRγ). Orphan nuclear receptors that regulate mitochondrial biogenesis, oxidative metabolism, and skeletal muscle energy substrate utilization without interacting with classical estrogen receptors. F40 Biotech’s formulation delivers 500mcg per tablet in a 50 count oral format. A precisely dosed presentation suited to the low concentration range at which ERR agonist activity has been documented in preclinical research models examining metabolic adaptation and exercise mimetic activity.
SLU-PP-332’s mechanism of action through ERRα and ERRγ co activation produces a coordinated upregulation of oxidative phosphorylation gene expression, mitochondrial biogenesis, and fatty acid oxidation pathway activity in skeletal muscle tissue, biological responses that closely mirror the transcriptional adaptations produced by endurance exercise training. This exercise mimetic profile has positioned SLU-PP-332 as one of the most actively discussed small molecule research compounds in contemporary metabolic science, with preclinical research documenting increased running endurance, enhanced oxidative muscle fiber characteristics, and improved metabolic flexibility in animal models. The ERR receptor pathway targeted by SLU-PP-332 is distinct from the AMPK pathway activated by compounds like MOTS-C and 5-Amino-1MQ; making it a complementary rather than redundant research tool in studies examining different molecular entry points into exercise adaptive metabolic regulation.
The oral tablet format is particularly well suited to SLU-PP-332 as a small molecule compound, unlike peptide research compounds that face gastrointestinal degradation requiring parenteral or intranasal delivery, small molecule ERR agonists are designed for oral bioavailability with gastrointestinal absorption and systemic distribution from standard tablet administration. At 500mcg per tablet this formulation provides precise low dose titration capability across research protocols examining ERR agonist dose response relationships in oxidative metabolism and mitochondrial biogenesis endpoints.
F40 Biotech formulations are stocked by Canada Steroid Depot following the same rigorous third party lab verification process applied to every product in our range. Each batch is tested for concentration accuracy and purity before being made available, with COA documentation available on request. CSD’s sourcing standards apply uniformly across all manufacturers we carry, and F40 Biotech’s SLU-PP-332 meets those standards consistently. All orders ship discreetly across Canada in plain, unmarked packaging with no identifying information on the exterior.
Store in a cool, dry place away from direct light and heat. Intended for research purposes only.
Commonly researched alongside MOTS-C and 5-Amino-1MQ in comparative metabolic regulation and exercise mimetic compound studies. Browse CSD’s full peptide and research compound range for complete sourcing.
SLU-PP-332 is a synthetic small molecule research compound that acts as an agonist of the estrogen related receptors ERRα, ERRβ, and ERRγ. These nuclear receptors regulate genes involved in mitochondrial function, oxidative metabolism, fatty acid utilization, and skeletal muscle adaptation. Each tablet contains 500mcg of SLU-PP-332, with 50 tablets providing 25mg total compound per bottle.
SLU-PP-332 is primarily investigated as an experimental exercise mimetic compound in preclinical research. Animal studies have examined its effects on oxidative skeletal muscle fibers, exercise endurance, mitochondrial metabolism, fatty acid oxidation, energy expenditure, insulin sensitivity, fat accumulation, and metabolic syndrome. Human therapeutic efficacy and safety have not been established.
SLU-PP-332 activates estrogen related receptors ERRα, ERRβ, and ERRγ, with particularly strong activity at ERRα. These nuclear receptors regulate transcriptional programs involved in mitochondrial biogenesis, oxidative phosphorylation, fatty acid oxidation, and cellular energy metabolism. Experimental activation of these pathways has produced exercise associated metabolic adaptations in animal models without requiring the compound to act as a stimulant.
Published research indicates that the original SLU-PP-332 compound has poor oral bioavailability. This is an important limitation of the compound despite its availability in tablet research formats. Researchers have subsequently developed related ERR agonists specifically to improve oral exposure. Human oral pharmacokinetics for SLU-PP-332 have not been established.
Yes! This batch is HPLC tested to verify SLU-PP-332 identity and content accuracy at 500mcg per tablet. Each bottle contains 50 tablets for 25mg total compound. A certificate of analysis is available.
![GLP-3 RTA [Triple G] - 10mg](https://www.canadasteroiddepot.is/wp-content/uploads/2024/10/HUD-GLP3-10-300x300.webp)
